AKAP7: A Promising Drug Target and Biomarker for ALS-Related Neuronal Degeneration

Target Name: AKAP7

NCBI ID: G9465

AKAP7

AKAP7: A Promising Drug Target and Biomarker for ALS-Related Neuronal Degeneration

Amyloid-related neurodegeneration (ALS) is a progressive neurodegenerative disorder that is characterized by the accumulation of misfolded amyloid peptides and the loss of neurotransmitter-producing neurons. The most common cause of ALS is the neurodegeneration associated with repetitive protein misfolding (NAM), which is caused by the presence of a specific protein called A-kinase anchor protein 7 (AKAP7).

The story of AKAP7 began in the late 1980s when researchers identified a protein that was consistently misfolded in individuals with spinocerebellar ataxia (SCA). This protein, named AKAP7, was found to be a key player in the misfolding and aggregation of beta-amyloid peptides, which are thought to play a central role in the development of neurodegenerative diseases.

Since then, numerous studies have demonstrated that AKAP7 is involved in the development and progression of a wide range of neurodegenerative disorders, including ALS. In this article, we will explore the role of AKAP7 in ALS and its potential as a drug target or biomarker.

The Misfolding of AKAP7

AKAP7 is a transmembrane protein that is expressed in a variety of tissues throughout the body, including brain, spleen, and pancreas. It is composed of two isoforms, alpha and beta, which are generated by alternative splicing of the gene. The alpha isoform is predominantly expressed in the brain, while the beta isoform is mainly expressed in the pancreas.

The misfolding of AKAP7 is thought to occur due to a variety of factors, including the presence ofAPP-尾, a misfolded form of the amyloid protein that is generated by the cleavage of APP by 尾-amyloid precursor protein (尾AP). When APP is cleaved by 尾-amyloid precursor protein (尾AP), it can formAPP-尾, which is then involved in the misfolding of AKAP7.

In addition to the presence ofAPP-尾, other factors have been shown to contribute to the misfolding of AKAP7. These include genetic variations in the AKAP7 gene, disruptions in the intracellular signaling pathway, and alterations in the levels of various proteins in the brain.

The Role of AKAP7 in ALS

The misfolding of AKAP7 has been linked to the development and progression of ALS, which is a progressive neurodegenerative disorder that is characterized by the accumulation of misfolded amyloid peptides and the loss of neurotransmitter-producing neurons. Studies have shown that individuals with the genetic variation in AKAP7 are more likely to develop ALS than those without the variation.

In addition to its role in the development of ALS, AKAP7 has also been shown to contribute to the progression of the disease. For example, studies have shown that individuals with ALS had lower levels of AKAP7 than those without the disease. Additionally, individuals with ALS had more misfolded copies of the AKAP7 protein than those without the disease.

The Potential of AKAP7 as a Drug Target

The misfolding of AKAP7 is a potential target for drug development in ALS. By targeting the misfolding of AKAP7, drugs could potentially reduce the production of misfolded AKAP7 protein and slow the progression of ALS.

One approach to targeting AKAP7 is to use small molecules that can modulate the activity of the protein. For example, recent studies have shown that inhibitors of the protein kinase A (IP3) can

Protein Name: A-kinase Anchoring Protein 7

Functions: Targets the cAMP-dependent protein kinase (PKA) to the plasma membrane, and permits functional coupling to the L-type calcium channel. The membrane-associated form reduces epithelial sodium channel (ENaC) activity, whereas the free cytoplasmic form may negatively regulate ENaC channel feedback inhibition by intracellular sodium

The "AKAP7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AKAP7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets